IP Library Granted Patent US 12,071,486
Granted Patent B2
US 12,071,486 · App. 16/230,326 · Granted Aug 27, 2024

Bispecific antigen binding construct

Inventors: Sebastian Van Der Woning (Bachte-Maria-Leerne, BE); Christophe Blanchetot (Destelbergen, BE)
Assignee: argenx BV
C07K16/468C07K2317/22C07K2317/31C07K2317/52C07K2317/526C07K2317/55C07K2317/569C07K2317/64C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,071,486
App. No.
16/230,326
Granted
Aug 27, 2024
Kind
B2
Abstract

The present invention relates to bispecific and other multispecific antigen binding constructs. In certain aspects, the invention relates to bispecific antigen binding constructs comprising a single domain antibody (VHH) antigen binding region fused to an IgG Fc domain; a heavy chain-Fc domain portion of a conventional IgG antibody, and a light chain portion of a conventional IgG antibody. The bispecific antigen binding constructs of the invention are capable of targeting two different antigens separately or in a protein complex.

Claims (7)

1. A bispecific antigen binding construct comprising

(a) a single VHH domain of a heavy-chain-only antibody (VHH antibody) which binds a first target antigen, wherein said VHH domain is fused to the N-terminus of a first human IgG 1 Fc domain polypeptide; and

(b) a single Fab portion of a conventional IgG antibody which binds a second target antigen, wherein said Fab portion is fused to the N-terminus of a second human IgG 1 Fc domain polypeptide;

wherein the first and second IgG 1 Fc domain polypeptides dimerize by knobs-into-holes interactions to form the bispecific antigen binding construct, and wherein the first human IgG 1 Fc domain polypeptide comprises tryptophan at EU position 366 , and the second human IgG 1 Fc domain polypeptide comprises serine, alanine, and valine at EU positions 366 , 368 , and 407 , respectively; or the second human IgG 1 Fc domain polypeptide comprises tryptophan at EU position 366 , and the first human IgG 1 Fc domain polypeptide comprises serine, alanine, and valine at EU positions 366 , 368 , and 407 , respectively.

2. A pharmaceutical composition comprising the bispecific antigen binding construct of claim 1 .

3. The bispecific antigen binding construct of claim 1 , wherein the conventional IgG antibody is obtained by immunization of an animal of the Camelidae family with the second target antigen.

4. The bispecific antigen binding construct of claim 1 , wherein the bispecific antigen binding construct has a molecular weight in the range of from about 100 kDa to about 120 kDa.

Assignments (2)
CHANGE OF NAME Recorded Apr 8, 2022
From: ARGENX BVBA
To: ARGENX BV
Reel/Frame 059539/0878 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2019
From: VAN DER WONING, SEBASTIAN; BLANCHETOT, CHRISTOPHE
To: ARGENX BVBA
Reel/Frame 050618/0820 →
Continuity (2)
Provisional Application 62609523 · Dec 22, 2017
Related Publication 20190218310A1 · Jul 18, 2019